FDG-PET as a biomarker for early response, in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?

Josée M Zijlstra, Coreline N Burggraaff, Marie José Kersten, and Sally F Barrington

Disclosures: Josee M. Zijlstra: Dutch Cancer Society, Roche, Takeda, Gilead. Coreline N. Burggraaff: Dutch Cancer Society. Marie José Kersten: Roche, Janssen, Gilead, Takeda. Sally F Barrington: King’s College London and UCL Comprehensive Cancer Imaging Centre is funded by the CRUK and EPSRC in association with the MRC and DoH (England)

Contributions: All authors have written the manuscript and participated sufficiently to take public responsibility for its content, and approved the final article.